Northern Virginia and Philadelphia, 10 January 2024 – Global law firm Hogan Lovells advised Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) on a research collaboration transaction with Novo Nordisk and Flagship Pioneering to develop a therapeutic for obesity management.
Omega is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases.
This collaboration will leverage Novo Nordisk’s expertise in research and development within cardiometabolic diseases and Omega’s proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.
Omega, Flagship’s Pioneering Medicines initiative, and Novo Nordisk will jointly advance this obesity management program through preclinical development and conduct foundational activities, after which point Novo Nordisk could further advance the program including through human proof-of-concept studies.
The Hogan Lovells team was led by partners Cullen Taylor (Northern Virginia) and Stephen Nicolai (Philadelphia), with support from senior attorney Melissa Schwaller (Houston), senior counsel Daniel Davidson (Washington, D.C.) and associate Estefania McCarroll (Northern Virginia).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
